ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1063

Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis in the Primary Care Setting

Kashif Jafri1, Lynne Taylor2, Nehal N. Mehta3, Melissa Nezamzadeh4, Joshua Baker5 and Alexis Ogdie6, 1Department of Medicine, University of Pennsylvania, Philadelphia, PA, 2Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 3Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 4University of Pennsylvania, Philadelphia, PA, 5Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 6Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Lipids, primary care and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Public Health (ACR): Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis has been associated with an increased risk of cardiovascular morbidity and mortality.  It is unclear, however, whether this knowledge has translated into improved screening and management of traditional cardiovascular risk factors such as hyperlipidemia in the primary care setting.  The objectives of this study included 1) To determine the prevalence of screening for hyperlipidemia in patients with rheumatoid arthritis (RA) that are followed by primary care physicians; 2) To examine whether current Adult Treatment Panel (ATP) III guidelines for the initiation of lipid-lowering therapy are being followed in patients with RA, and 3) to assess whether proposed modifications to cardiovascular risk calculations change the percentage of RA patients with an indication for therapy.

Methods: A retrospective cohort study was performed among patients with RA in an academic medical center medical record database in the United States between 2005-2010.  A validation study prior to initiation of the study demonstrated a positive predictive value of 96.7% for accurate capture of patients with RA using ICD-9 codes.  Descriptive statistics were used to report the prevalence of screening and use of lipid-lowering therapy (LLT) among those with an indication for LLT.  Factors associated with not receiving lipid screening were examined using logistic regression models.  Finally, indication for and receipt of therapy were assessed following application of the European Union League Against Rheumatism (EULAR) recommended multiplier to the Framingham risk score.

Results: Among 1418 patients with RA followed by primary care physicians, lipid screening was ordered for 780 (55%) within the 3-year follow-up period.  Patients under the age of 50 were significantly less likely to be screened whereas patients with diabetes, hypertension, chronic kidney disease, and obesity were more likely to be screened (Table).  Of those with lipid results (N=419), 50 (12%) patients had an indication for LLT based on the ATP III guidelines.  Among the 50 patients with an indication for LLT, 38 (76%) received therapy.  Applying the EULAR multiplier only changed the indication for LLT in two patients.

Conclusion: Although patients with RA have an increased risk for cardiovascular disease, they are often not receiving optimal management of traditional cardiovascular risk factors, such as screening for hyperlipidemia.  Nevertheless, once hyperlipidemia has been identified, most patients received the appropriate lipid-lowering therapy.  The EULAR multiplier does not seem to have a measurable impact on clinical care, and new methods for assessing cardiovascular risk among patients with RA are needed.

Table. Logistic regression models for non-receipt of screening*

 

 

Univariable

Final

Multivariable Model*

 

 

OR (95%CI)

OR (95%CI)

Age (<50)

 

1.74 (1.38-2.19)

1.65 (1.30-2.10)

Sex (F)

 

1.08 (0.81-1.43)

 

Race

Caucasian

Ref

 

 

Black or African American

0.76 (0.61-0.95)

 

 

Asian

1.26 (0.60-2.64)

 

 

Other or unknown

1.60 (1.04-2.48)

 

Hypertension

 

0.30 (0.21-0.42)

0.40 (0.28-0.57)

Hyperlipidemia Diagnosis

0.17 (0.10-0.31)

 

Diabetes mellitus

 

0.41 (0.31-0.53)

0.47 (0.36-0.63)

Obesity

 

0.37 (0.25-0.56)

0.44 (0.28-0.68)

Peripheral Arterial Disease

0.13 (0.02-1.06)

 

Tobacco use (n=564)

Current smoker vs non-smoker or past-smoker

1.50 (1.00-2.23)

 

Note that odds ratios (OR) refer to NOT receiving screening.  For example, age <50 is associated with an increased risk of NOT receiving screening by a factor of 1.95. *c=0.65 for the association between predicted probabilities and observed responses for the final multivariable model.

 


Disclosure:

K. Jafri,
None;

L. Taylor,
None;

N. N. Mehta,
None;

M. Nezamzadeh,
None;

J. Baker,
None;

A. Ogdie,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/management-of-hyperlipidemia-among-patients-with-rheumatoid-arthritis-in-the-primary-care-setting/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology